Cardea Bio

# Cardea Bio: High-Level Overview

Cardea Bio is a biotech company developing graphene-based biosensing chips that convert biological signals into electrical data for rapid diagnostics.[1][3] Founded in 2013 (originally as Nanomedical Diagnostics), the company specializes in creating biology-gated transistors—proprietary semiconductor devices that enable real-time detection of molecular biomarkers without traditional optical methods.[1][2] The company was acquired by UK-based Paragraf in May 2023 and now operates as Paragraf USA.[5]

Cardea's core mission is to democratize precision healthcare by making diagnostics faster, cheaper, and more accessible—particularly in developing countries.[3][6] Rather than building a single diagnostic tool, the company has developed a modular platform of graphene-based biosensors (called Biosignal Processing Units or BPUs) that can be configured for different applications: the CRISPR-Chip for genetic detection, the SNP-Chip for single nucleotide polymorphisms, and the EV-Chip for exosome biomarkers linked to cancer and aging-related diseases.[2][4] This flexibility allows partners to build custom diagnostic products addressing diverse clinical needs.

# Origin Story

Cardea was established in late 2013 to develop cutting-edge diagnostics equipment using graphene-based sensors.[5] The company began shipping its first systems in 2016, including the AGILE R100 system for real-time detection of small molecules.[5] Under the leadership of CEO Michael Heltzen, Cardea built a decade of expertise in graphene electronics and molecular detection, publishing peer-reviewed research demonstrating clinical applications—notably a 2021 paper in *Advanced Biology* on the EV-Chip's ability to detect cancer and aging biomarkers.[4]

The acquisition by Paragraf in May 2023 marked a pivotal moment, combining Cardea's world-leading biosensing IP with Paragraf's breakthrough in scalable, mass-produced monolayer graphene production.[7] This union positioned the company to move from prototype to commercial scale.

# Core Differentiators

• Graphene-based architecture: Unlike silicon-based semiconductors, Cardea's BioFETs use biocompatible graphene that is conductive yet biologically inert, enabling direct electrical signal detection without optical intermediaries.[1][6]

• Multi-omics streaming data: The Cardean transistor generates real-time, continuous biological data streams rather than snapshot measurements, allowing partners to capture unprecedented amounts and types of biological information.[1]

• Modular platform approach: A single core technology (the BPU) can be reconfigured for different biomarkers and diseases—CRISPR-based genetic detection, SNP analysis, exosome detection, and volatile compound sensing—reducing development time for new applications.[4][6]

• Manufacturing at scale: Post-acquisition, Paragraf's transfer-free monolayer graphene production enables mass manufacturing of chips, moving Cardea from prototype to commercial viability.[7]

• Handheld, field-deployable design: The company targets portable, low-cost readers suitable for resource-limited settings, addressing a critical gap in global diagnostics.[4][6]

# Role in the Broader Tech Landscape

Cardea sits at the intersection of three powerful trends: the shift from silicon to alternative semiconductors, the rise of precision medicine, and the push for decentralized diagnostics. As traditional silicon-based electronics approach physical limits, graphene and 2D materials represent a genuine frontier in semiconductor innovation.[7] Simultaneously, the diagnostics industry is moving away from centralized lab infrastructure toward rapid, point-of-care testing—a shift accelerated by the COVID-19 pandemic and growing demand for early disease detection.

The company's work directly addresses a critical market need: most advanced diagnostics remain confined to well-equipped laboratories in wealthy nations. By combining molecular biology with semiconductor electronics, Cardea enables diagnostic capabilities previously impossible in field or developing-world settings. The Bill and Melinda Gates Foundation's $1.1 million grant for infectious disease detection underscores the global health relevance of this approach.[6][8]

Cardea's acquisition by Paragraf also signals broader industry consolidation around graphene electronics, positioning the combined entity as a leader in next-generation biosensing infrastructure.

# Quick Take & Future Outlook

Cardea's trajectory suggests a company transitioning from R&D validation to commercial deployment. With Paragraf's manufacturing capabilities now backing its technology, the near-term focus will likely be scaling production and bringing the electronic nose for infectious disease detection to market—particularly in developing countries where the Gates Foundation partnership provides both funding and credibility.[6][8]

The longer-term opportunity is substantial: if the modular BPU platform proves as versatile as early applications suggest, Cardea could become foundational infrastructure for precision diagnostics across oncology, infectious disease, genetic disorders, and environmental monitoring. The company's success will hinge on whether graphene-based biosensors can achieve the reliability, cost, and ease of use required for widespread adoption—and whether Paragraf's manufacturing prowess can deliver on that promise at scale.